How to buy Anixa Biosciences stock

Anixa Biosciences, Inc is a diagnostics & research business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Anixa Biosciences employs 3 staff and has a trailing 12-month revenue of around 0.00.

Anixa Biosciences share price

Use our graph to track the performance of ANIX stocks over time.

Anixa Biosciences shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$1.70 - $8.09
50-day moving average	$5.03
200-day moving average	$3.81
Wall St. target price	$9.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.77

Buy Anixa Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Anixa Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Anixa Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anixa Biosciences financials

Revenue TTM	$512,500
Gross profit TTM	$83,750
Return on assets TTM	-55.64%
Return on equity TTM	-107.41%
Profit margin	0%
Book value	$0.52
Market capitalisation	$155.4 million

TTM: trailing 12 months

Shorting Anixa Biosciences shares

There are currently 529,090 Anixa Biosciences shares held short by investors – that's known as Anixa Biosciences's "short interest". This figure is 18.7% down from 650,478 last month.

There are a few different ways that this level of interest in shorting Anixa Biosciences shares can be evaluated.

Anixa Biosciences's "short interest ratio" (SIR)

Anixa Biosciences's "short interest ratio" (SIR) is the quantity of Anixa Biosciences shares currently shorted divided by the average quantity of Anixa Biosciences shares traded daily (recently around 778073.52941176). Anixa Biosciences's SIR currently stands at 0.68. In other words for every 100,000 Anixa Biosciences shares traded daily on the market, roughly 680 shares are currently held short.

However Anixa Biosciences's short interest can also be evaluated against the total number of Anixa Biosciences shares, or, against the total number of tradable Anixa Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anixa Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Anixa Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0185% of the tradable shares (for every 100,000 tradable Anixa Biosciences shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anixa Biosciences.

Find out more about how you can short Anixa Biosciences stock.

Anixa Biosciences share dividends

We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.

Have Anixa Biosciences's shares ever split?

Anixa Biosciences's shares were split on 17 October 2016.

Anixa Biosciences share price volatility

Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $1.7 up to $8.09. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 1.449. This would suggest that Anixa Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Anixa Biosciences overview

Anixa Biosciences, Inc. , a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc.

Frequently asked questions

• What percentage of Anixa Biosciences is owned by insiders or institutions?

  Currently 8.983% of Anixa Biosciences shares are held by insiders and 5.832% by institutions.

• How many people work for Anixa Biosciences?

  Latest data suggests 3 work at Anixa Biosciences.

• When does the fiscal year end for Anixa Biosciences?

  Anixa Biosciences's fiscal year ends in October.

• Where is Anixa Biosciences based?

  Anixa Biosciences's address is: 3150 Almaden Expressway, San Jose, CA, United States, 95118

• What is Anixa Biosciences's ISIN number?

  Anixa Biosciences's international securities identification number is: US03528H1095

• What is Anixa Biosciences's CUSIP number?

  Anixa Biosciences's Committee on Uniform Securities Identification Procedures number is: 03528H109